Inventor
GOZES ILLANA
IL30 patents
⚠️ This page may combine multiple inventors who share the name “GOZES ILLANA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV RAMOT
12 patentsUS6613740B1Sep 2, 2003
Activity dependent neurotrophic factor III (ADNF III)
UNIV RAMOT49 citations95
US7452867B2Nov 18, 2008
Use of ADNF polypeptides for treating peripheral neurotoxicity
UNIV RAMOT27 citations93
US6174862B1Jan 16, 2001
Neurotrophic peptides of activity dependent neurotrophic factor
UNIV RAMOT46 citations92
US7863247B1Jan 4, 2011
Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides
UNIV RAMOT17 citations91
US6933277B2Aug 23, 2005
Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides
UNIV RAMOT28 citations91
US5565424AOct 15, 1996
Superactive VIP antagonists
UNIV RAMOT29 citations91
US6630124B1Oct 7, 2003
Combination therapy with VIP antagonist
UNIV RAMOT55 citations90
US7960334B2Jun 14, 2011
Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia
UNIV RAMOT6 citations68
US10118943B2Nov 6, 2018
Compounds and methods for inhibiting cell death
UNIV RAMOT4 citations67
US10912819B2Feb 9, 2021
Neuroprotective peptides derived from activity-dependent neuroprotective protein for treatment of neurological diseases
UNIV RAMOT0 citations62
US8377875B2Feb 19, 2013
Therapeutics based on tau/microtubule dynamics
UNIV RAMOT4 citations57
US10822375B2Nov 3, 2020
Method for identifying a modulator of cell survival or plasticity
UNIV RAMOT0 citations46
US HEALTH
8 patentsUS5767240AJun 16, 1998
Activity-dependent neurotrophic factor
US HEALTH33 citations92
US7264947B2Sep 4, 2007
Activity dependent neurotrophic factor III (ADNF III)
US HEALTH26 citations91
US7384908B1Jun 10, 2008
Orally active peptides that prevent cell damage and death
US HEALTH17 citations90
US6649411B2Nov 18, 2003
Methods of inhibiting cancer cells with ADNF III antisense oligonucleotides
US HEALTH22 citations90
US5217953AJun 8, 1993
Vasoactive intestinal peptide antagonist
US HEALTH30 citations89
US7427598B2Sep 23, 2008
Post-natal administration of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory
US HEALTH15 citations80
US7427590B2Sep 23, 2008
Neurothrophic components of the ADNF I complex
US HEALTH15 citations80
US8017578B2Sep 13, 2011
Orally active peptides that prevent cell damage and death
US HEALTH6 citations70
GOZES ILLANA
6 patentsUS8324166B2Dec 4, 2012
Neuroprotection using NAP-like and SAL-like peptide mimetics
GOZES ILLANA10 citations76
US9518994B2Dec 13, 2016
Method for diagnosing and monitoring schizophrenia and tauopathies
GOZES ILLANA3 citations64
US8586548B2Nov 19, 2013
NAP alpha-aminoisobutyric acid analog with neuroprotective activity
GOZES ILLANA2 citations62
US8143221B2Mar 27, 2012
Use of ADNF polypeptides for treating peripheral neurotoxicity
GOZES ILLANA4 citations62
US8067369B2Nov 29, 2011
Protection of the retina against laser injury by NAP and related peptides
GOZES ILLANA4 citations62
US8618043B2Dec 31, 2013
Use of ADNF polypeptides for treating anxiety and depression
GOZES ILLANA2 citations57
YEDA RES & DEV
4 patentsUS6239107B1May 29, 2001
Conjugates of lipophilic moieties and fragments of vasoactive intestinal peptide (VIP)
YEDA RES & DEV47 citations92
US5972883AOct 26, 1999
Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
YEDA RES & DEV37 citations92
US5147855ASep 15, 1992
Conjugates of vip and active fragments thereof with hydrophobic moieties and topical compositions for male impotence
YEDA RES & DEV36 citations92
US5998368ADec 7, 1999
Derivatives of structurally modified VIP and pharmaceutical compositions containing them
YEDA RES & DEV14 citations74